Research

Hormonal

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) improve glycemic control in type 2 diabetes by blocking glucose reabsorption in the renal proximal tubule, inducing glycosuria.

If you have Type 2 Diabetes and your kidneys are functioning adequately (eGFR > 30), SGLT2 inhibitors like empagliflozin or dapagliflozin can help lower your blood sugar by causing your kidneys to excrete glucose in your urine. This is done via a daily oral pill. While there is a risk of genital infections, they are generally mild and manageable. The key benefit is that these drugs also offer cardiovascular and renal protection beyond just lowering blood sugar.

GoodSupportsHIGH confidence
SGLT2 inhibitors exert multiple beneficial effects, including reductions in body weight and serum uric acid (SUA) as well as BP lowering and attenuation of glomerular hyperfiltration, which are likely linked to glycosuria-accompanied natriuresis.
Erik J.M. van Bommel et al. · Clinical Journal of the American Society of Nephrology · 2017

Why this rating

Based on a meta-analysis of 45 clinical trials including 11,232 patients.

Source

SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome

Erik J.M. van Bommel et al. · Clinical Journal of the American Society of Nephrology · 2017

DOI 10.2215/cjn.06080616

narrative_reviewCited 219×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →